trending Market Intelligence /marketintelligence/en/news-insights/trending/gypqohf6k4wwvyv9rzlvta2 content esgSubNav
In This List

DanDrit Biotech applies to list on Nasdaq

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


DanDrit Biotech applies to list on Nasdaq

DanDrit Biotech USA Inc. filed an application to list its common shares on the Nasdaq Capital Market following the acquisition of privately held Enochian Biopharma Inc.

The Danish biopharmaceutical company will change its name to Enochian BioSciences Inc. and relocate its headquarters to Los Angeles. It is currently listed on the OTC Pink market.

DanDrit specializes in developing immunotherapies for various types of cancer and is currently working on innovative treatments for HIV and colon cancer.